382 related articles for article (PubMed ID: 11054441)
1. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Patnaik A; Warner E; Michael M; Egorin MJ; Moore MJ; Siu LL; Fracasso PM; Rivkin S; Kerr I; Litchman M; Oza AM
J Clin Oncol; 2000 Nov; 18(21):3677-89. PubMed ID: 11054441
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
Fracasso PM; Westervelt P; Fears CL; Rosen DM; Zuhowski EG; Cazenave LA; Litchman M; Egorin MJ
J Clin Oncol; 2000 Mar; 18(5):1124-34. PubMed ID: 10694566
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
Lhommé C; Joly F; Walker JL; Lissoni AA; Nicoletto MO; Manikhas GM; Baekelandt MM; Gordon AN; Fracasso PM; Mietlowski WL; Jones GJ; Dugan MH
J Clin Oncol; 2008 Jun; 26(16):2674-82. PubMed ID: 18509179
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Villalona-Calero MA; Weiss GR; Burris HA; Kraynak M; Rodrigues G; Drengler RL; Eckhardt SG; Reigner B; Moczygemba J; Burger HU; Griffin T; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Jun; 17(6):1915-25. PubMed ID: 10561233
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
Oka M; Fukuda M; Nagashima S; Fukuda M; Kinoshita A; Soda H; Doi S; Narasaki F; Suenaga M; Takatani H; Nakamura Y; Kawabata S; Tsurutani J; Kanda T; Kohno S
Cancer Chemother Pharmacol; 2001 Dec; 48(6):446-50. PubMed ID: 11800024
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Huizing MT; Giaccone G; van Warmerdam LJ; Rosing H; Bakker PJ; Vermorken JB; Postmus PE; van Zandwijk N; Koolen MG; ten Bokkel Huinink WW; van der Vijgh WJ; Bierhorst FJ; Lai A; Dalesio O; Pinedo HM; Veenhof CH; Beijnen JH
J Clin Oncol; 1997 Jan; 15(1):317-29. PubMed ID: 8996159
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Chico I; Kang MH; Bergan R; Abraham J; Bakke S; Meadows B; Rutt A; Robey R; Choyke P; Merino M; Goldspiel B; Smith T; Steinberg S; Figg WD; Fojo T; Bates S
J Clin Oncol; 2001 Feb; 19(3):832-42. PubMed ID: 11157037
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
Stinchcombe TE; Socinski MA; Walko CM; O'Neil BH; Collichio FA; Ivanova A; Mu H; Hawkins MJ; Goldberg RM; Lindley C; Dees EC
Cancer Chemother Pharmacol; 2007 Oct; 60(5):759-66. PubMed ID: 17285317
[TBL] [Abstract][Full Text] [Related]
13. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Patnaik A; Wood D; Tolcher AW; Hamilton M; Kreisberg JI; Hammond LA; Schwartz G; Beeram M; Hidalgo M; Mita MM; Wolf J; Nadler P; Rowinsky EK
Clin Cancer Res; 2006 Dec; 12(24):7406-13. PubMed ID: 17189413
[TBL] [Abstract][Full Text] [Related]
14. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Leong S; Cohen RB; Gustafson DL; Langer CJ; Camidge DR; Padavic K; Gore L; Smith M; Chow LQ; von Mehren M; O'Bryant C; Hariharan S; Diab S; Fox NL; Miceli R; Eckhardt SG
J Clin Oncol; 2009 Sep; 27(26):4413-21. PubMed ID: 19652058
[TBL] [Abstract][Full Text] [Related]
15. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Belani CP; Aisner J; Hiponia D; Engstrom C
Semin Oncol; 1995 Aug; 22(4 Suppl 9):7-12. PubMed ID: 7544028
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
Advani R; Fisher GA; Lum BL; Hausdorff J; Halsey J; Litchman M; Sikic BI
Clin Cancer Res; 2001 May; 7(5):1221-9. PubMed ID: 11350887
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
